Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Non-Current Assets (2017 - 2025)

Historic Non-Current Assets for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $173.0 million.

  • Denali Therapeutics' Non-Current Assets fell 7043.22% to $173.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 2960.41%. This contributed to the annual value of $509.7 million for FY2024, which is 46777.01% up from last year.
  • Latest data reveals that Denali Therapeutics reported Non-Current Assets of $173.0 million as of Q3 2025, which was down 7043.22% from $231.5 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Non-Current Assets ranged from a high of $607.5 million in Q1 2024 and a low of $81.7 million during Q2 2023
  • Its 5-year average for Non-Current Assets is $278.8 million, with a median of $177.9 million in 2022.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 8265.57% in 2022, then skyrocketed by 62166.97% in 2024.
  • Over the past 5 years, Denali Therapeutics' Non-Current Assets (Quarter) stood at $506.9 million in 2021, then crashed by 82.66% to $87.9 million in 2022, then rose by 2.11% to $89.8 million in 2023, then soared by 467.77% to $509.7 million in 2024, then plummeted by 66.06% to $173.0 million in 2025.
  • Its last three reported values are $173.0 million in Q3 2025, $231.5 million for Q2 2025, and $392.7 million during Q1 2025.